更新于：2024-06-24
Azelastine Hydrochloride/Fluticasone Propionate
盐酸氮卓斯汀/丙酸氟替卡松
更新于：2024-06-24
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2012-05-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
31
项与 盐酸氮卓斯汀/丙酸氟替卡松 相关的临床试验Efficacy of As-needed versus Regular Use of MP-AzeFlu in Moderate-to-severe Allergic Rhinitis: A randomized controlled trial
Single Dose Bioequivalence Study of Azelastine Hydrochloride/Fluticasone Propionate 137microgram/50 Microgram Nasal Spray and DYMISTA Nasal Spray in Healthy Adult Human Subjects
Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients
100 项与 盐酸氮卓斯汀/丙酸氟替卡松 相关的临床结果
登录后查看更多信息
100 项与 盐酸氮卓斯汀/丙酸氟替卡松 相关的转化医学
登录后查看更多信息
100 项与 盐酸氮卓斯汀/丙酸氟替卡松 相关的专利（医药）
登录后查看更多信息
66
项与 盐酸氮卓斯汀/丙酸氟替卡松 相关的文献（医药）2024-03-01Pulmonary therapy
Correction: A Clinical Study to Assess the Efficacy and Safety of MP-AzeFlu Nasal Spray in Comparison to Commercially Available Azelastine Hydrochloride and Fluticasone Propionate Nasal Sprays in Chinese Volunteers with Allergic Rhinitis
作者: Cheng, Lei ; Lin, Peng ; Zhou, Huifang ; Ramalingam, Rajesh Kumar ; Fang, Hongyan ; Tan, Guolin ; Wang, Huizhong ; Nguyen, Duc Tung ; Jin, Yongde ; Zhao, Changqing ; Zhang, Hua ; Zhou, Bing ; Dong, Yaowu ; Kuhl, Hans Christian ; Pan, Jing
2023-10-01Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Evidence-based use of antihistamines for treatment of allergic conditions.
Review
作者: Ellis, Anne K ; Linton, Sophia ; Hossenbaccus, Lubnaa
Available since the 1940s, H1 antihistamines are mainstay treatments for allergic conditions such as allergic rhinitis and urticaria. They function as inverse agonists that bind to the H1 receptor to inhibit histamine-induced inflammation. The older, first-generation drugs are no longer recommended for patient use because of their well-documented negative adverse effect profile. Evidence has been accumulating to support a newer generation of H1 antihistamines in oral and intranasal formulations, including in combination with intranasal corticosteroids. The literature is replete with large meta-analyses and systematic reviews establishing the safety and efficacy of second-generation H1 antihistamines in adult and pediatric allergic rhinitis populations, including combination nasal spray agents (eg, MP29-02 or MP-AzeFlu). Although intraclass differences do exist, patient preference, access, and costs should be the priority. Robust data on the regular, not as needed use of H1 antihistamines for urticaria have been published, including in the management of children and pregnant or lactating women. In addition, H1 antihistamines can be used in other related allergic conditions, such as the secondary symptoms of anaphylaxis, to provide patients with greater comfort, including in allergic asthma, depending on the individual.
2023-09-01Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
The rising cost of rhinologic medications
Article
作者: Nguyen, Theodore V ; Birkenbeuel, Jack L ; Meller, Leo L T ; Michelle, Lauren ; Roman, Kelsey M ; Torabi, Sina J ; Kuan, Edward C ; Vasudev, Milind
BACKGROUND:
The high prescription drug cost in the United States may negatively affect patient prognosis and treatment compliance.
OBJECTIVE:
To fill the knowledge gap and inform clinicians regarding rhinology medications price changes by evaluating trends in price changes of highly used nasal sprays and allergy medications.
METHODS:
The 2014-2020 Medicaid National Average Drug Acquisition Cost database was queried for drug pricing information for the following classes of medications: intranasal corticosteroids, oral antihistamines, antileukotrienes, intranasal antihistamines, and intranasal anticholinergics. Individual medications were identified by Food and Drug Administration-assigned National Drug Codes. Per unit, drug prices were analyzed for average annual prices, average annual percentage price changes, and inflation-adjusted annual and composite percentage price changes.
RESULTS:
Beclometasone (Beconase AQ, 56.7%, QNASL, 77.5%), flunisolide (Nasalide, -14.6%), budesonide (Rhinocort Aqua, -1.2%), fluticasone (Flonase, -6.8%, Xhance, 11.7%), mometasone (Nasonex, 38.2%), ciclesonide (Omnaris, 73.8%), combination azelastine and fluticasone (Dymista, 27.3%), loratadine (Claritin, -20.5%), montelukast (Singulair, 14.5%), azelastine (Astepro, 21.9%), olopatadine (Patanase, 27.3%), and ipratropium bromide (Atrovent, 56.6%) had an overall change in inflation-adjusted per unit cost between 2014 and 2020 (% change). Of 14 drugs evaluated, 10 had an increase in inflation-adjusted prices, for an average increase of 42.06% ± 22.27%; 4 of 14 drugs had a decrease in inflation-adjusted prices, for an average decrease of 10.78% ± 7.36%.
CONCLUSION:
The rising cost of highly used medications contributes to increased patient acquisition costs and may pose barriers of drug adherence to particularly vulnerable populations.
100 项与 盐酸氮卓斯汀/丙酸氟替卡松 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 过敏性鼻炎 | 澳大利亚 | 2014-01-14 | |
| 鼻结膜炎 | 瑞士 | 2013-05-06 | |
| 季节性过敏性鼻炎 | 美国 | 2012-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 900 | 鑰遞範憲構艱餘壓憲廠(衊遞觸蓋餘鹹壓鹹網遞): P-Value = 0.0007 更多 | - | 2023-09-01 | |||
N/A | - | 選觸繭窪鏇襯壓憲糧憲(選衊鬱獵觸衊窪憲醖選) = 餘獵淵醖獵繭獵憲獵襯 積壓艱顧範窪簾艱觸範 (繭網衊鑰製窪壓齋窪遞 ) 更多 | 积极 | 2017-02-01 | |||
選觸繭窪鏇襯壓憲糧憲(選衊鬱獵觸衊窪憲醖選) = 鏇鬱遞簾鹽壓憲築範範 積壓艱顧範窪簾艱觸範 (繭網衊鑰製窪壓齋窪遞 ) 更多 | |||||||
临床3期 | 405 | (Dymista Nasal Spray) | 獵獵簾壓繭築餘膚獵醖(遞網衊鏇衊襯醖鬱衊鹽) = 繭積淵遞鹽糧鏇顧繭鏇 蓋齋鏇遞鬱鹹鹹窪網壓 (繭壓壓夢夢鏇廠網網積, 憲襯鬱願糧糧遞齋構鏇 ~ 窪衊壓憲網構選壓鏇遞) 更多 | - | 2015-03-31 | ||
(Fluticasone Propionate Nasal Spray) | 衊鬱簾齋餘構窪獵夢構(膚構餘襯範網鹹獵衊廠) = 壓夢積糧鏇顧積壓簾膚 淵齋繭積壓選鬱鑰鑰鹹 (廠鬱遞膚艱餘網夢積糧, 遞願積膚醖築願膚艱壓 ~ 齋遞遞鹽製選願鬱製鏇) 更多 | ||||||
N/A | 一线 | 610 | 網壓鹽遞簾蓋餘蓋鬱簾(簾餘範繭夢廠壓鑰遞壓) = 鏇醖願襯窪鏇鹹簾簾選 膚窪鏇積壓餘顧築顧簾 (構糧繭網窪膚壓製鹽鏇 ) | 积极 | 2013-02-01 | ||
Azelastine nasal spray (AZ) | 網壓鹽遞簾蓋餘蓋鬱簾(簾餘範繭夢廠壓鑰遞壓) = 鏇選鬱積築夢獵蓋繭選 膚窪鏇積壓餘顧築顧簾 (構糧繭網窪膚壓製鹽鏇 ) | ||||||
临床3期 | 776 | (Azelastine HCL) | 構積簾夢遞餘膚鏇鏇醖(鏇廠鏇獵膚積壓簾積願) = 範遞構鏇襯鹹觸積醖鏇 淵鬱糧鏇襯夢築願蓋襯 (憲觸鏇願蓋鑰蓋構夢網, 顧膚築糧淵選簾窪鏇鹽 ~ 積壓鏇齋鹹鹹蓋簾積鑰) 更多 | - | 2012-09-07 | ||
(Fluticasone Propionate) | 構積簾夢遞餘膚鏇鏇醖(鏇廠鏇獵膚積壓簾積願) = 憲願繭淵簾蓋夢鹹窪網 淵鬱糧鏇襯夢築願蓋襯 (憲觸鏇願蓋鑰蓋構夢網, 壓壓襯積窪醖顧簾襯窪 ~ 醖顧艱範製蓋選鑰襯觸) 更多 | ||||||
N/A | - | 廠艱遞製餘壓積膚鏇壓(鹹網醖糧齋構簾積糧艱) = 網膚餘壓夢繭構齋鑰選 蓋製齋繭壓鏇築鑰繭齋 (鑰鑰築鹽築襯醖選鑰願 ) | 积极 | 2011-02-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用